Patients w/ CV disease due to possibility of fluid retention. Regular liver function testing. Hepatic impairment. Stop therapy or reduced dosage if there is evidence of hepatotoxicity.
Terfenadine, astemizole, & cisapride & other drugs w/ narrow therapeutic index that are metabolised by cytochrome P450 isoenzymes. May displace warfarin from protein binding sites.
Sign Out
